Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in Xinjiang, China: a prospective study

Xinji Gong,† Yuehua Li,† Jing Wang,* Gang Wu, Ayinuer Mohemaiti, Qimanguli Wushouer, Lidan Yao, Jianghua Lv, Rongrong Li, Pengfei Li and Buqing Wang

Background: Despite great effort to control tuberculosis (TB), low treatment adherence threatens the success of drug therapy, increases the risk of TB transmission, and leads to the development of drug resistance. The present study assessed anti-TB treatment adherence in sputum smear-positive TB patients and examined the risk factors for poor patient adherence to identify targets for intervention.

Methods: We monitored and followed up TB patients who were diagnosed between July 2014 and June 2015 in Xinjiang, China. A total of 8289 sputum smear-positive TB patients were included in this study. All patients registered their information during the first hospital visit or with the Centers for Disease Control, had regular follow-up visits, and accepted the anti-TB treatment. Insufficient re-examination adherence was defined as undergoing fewer than the recommended three sputum smear examinations during the treatment course. Results: Among 8289 patients, 3827 men (84.4% of male patients) and 3220 women (85.7% of female patients) had good adherence during treatment follow-up. 1242 patients (15.0%) did not complete regular follow-up. 332 (4.0%) patients lost contact. An adjusted logistic regression model showed that ethnicity, household address, treatment classification, patient source, and the actual management were significantly associated with non-adherence. Conclusion: The Xinjiang TB epidemic situation remains grim. Smear-positive patients had a higher proportion of non-adherence, which increased treatment difficulties and the risk of death from TB. Relevant medical departments should strengthen their supervision and interventions during the TB treatment process to improve patient adherence to anti-TB treatment.

Introduction

Tuberculosis (TB) causes significant morbidity and mortality and remains a major global health problem.† According to the 2015 World Health Organization (WHO) Global TB Control Report, 10.4 million new cases of TB were diagnosed in 2015. There were an estimated 1.4 million TB deaths in 2015, and an additional 0.4 million deaths resulted from TB disease among people living with HIV. However, globally, there were 4.3 million more actual cases of disease than reported.‡ Currently, approximately one-third of the world’s population is infected with TB bacteria.‡ Therefore, TB can have far-reaching economic and social consequences among infected people and their household members, particularly in developing countries.‡

China accounts for 15% of the global burden of TB and has the third highest TB incidence rate in the world behind India and Indonesia. Data from the Fifth National TB Epidemiological Survey in 2010 showed that China’s active TB prevalence was 459/100 000, with 66/1 000 000 representing sputum smear-positive TB.¶ The Xinjiang Uyghur Autonomous Region (Xinjiang) is located in northwestern China, with international borders with Russia, Mongolia, Kazakhstan, Kyrgyzstan, Tajikistan, Afghanistan, Pakistan, and India, with a population of 20 million people and 13 ethnic minorities.¶ Xinjiang is one of the provinces in China with a high burden of TB.¶ Xinjiang is one of the provinces with high burden of TB in China. Its economy is relatively backward, its public health infrastructure is weak and its medical resources are scarce. Many problems exist in the process of diagnosis, treatment and management of TB, which leads to the high number of patients and their
constant transmission has become the thorniest challenge in tuberculosis control in China.

Within the international TB control strategy, direct observation of treatment (DOT) was introduced to improve treatment outcomes. A standard anti-TB treatment requires patients to regularly take a complex combination of drugs for at least 6 months for new patients and 8 or 9 months for those undergoing repeat retreatment. Such long-term strict regimens are a challenge for TB patients who may not adhere to their prescribed treatment due to treatment interruptions or drop-out. Adherence to treatment is crucial to achieving a successful treatment outcome. Poor adherence to treatment may prolong infectiosity and increase the risk of drug resistance, relapse, death, and onward transmission. Rocha et al. showed that treatment non-adherence was significantly associated with unfavorable outcomes (death or failure to cure TB). Other studies on adherence have shown improved TB cure rates. In recent years, many cities in China have performed studies of TB treatment outcome, and the results indicated low treatment adherence among smear-positive TB patients.

We conducted surveillance and follow-up of TB treatment in major cities in Xinjiang to evaluate patient compliance with anti-TB treatment and to determine the risk factors of non-adherence in smear-positive TB patients. This study provides a theoretical basis for the next step in developing measures to improve patient compliance in accordance with the TB situation in Xinjiang.

Methods

Pulmonary tuberculosis diagnosis

The diagnosis of pulmonary TB patients in Xinjiang was based on the People’s Republic of Health Industry standard diagnostic criteria for TB (WS288-2008). Patients were considered to have smear-positive pulmonary TB when they met one of the following 3 criteria: 2 sputum specimens directly showing smear-positive acid-fast bacilli; 1 sputum specimen directly showing acid-fast bacilli with a positive microscopic examination and pulmonary imaging in line with the performance of active pulmonary TB imaging; or 1 sputum specimen directly showing smear-positive acid-fast bacilli and 1 sputum specimen that was Mycobacterium tuberculosis culture-positive.

Pulmonary tuberculosis treatment

The treatment regimen for new cases of TB consisted of a two-month intensive phase with a daily dose of fixed-dose combination tablets containing rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), followed by a four-month continuation phase of daily HR. New patients underwent three re-examinations for sputum smear microscopy to monitor treatment response after the second, fifth, and sixth (eighth) months of treatment. The repeat treatment patients underwent a three-month intensive phase including the four drugs above along with a six-month continuation phase of daily HRE. At the end of the course of 2, 5, or 8 months, the patients returned for re-examinations. Smear-positive patients are expected to convert to negative status after two months of intensive treatment. During the 2 month treatment period, if the patient’s sputum smears were still positive, they were prescribed an additional sputum smear at the end of the third month and an additional month of the intensive phase treatment.

TB management

The tuberculosis management in Xinjiang uses the whole process of supervision and management, since the 2012 implementation of the “Trinity” new TB prevention and control of new models, a prevention and treatment service system of designated medical institutions, primary health care institutions and the CDC, with clear division and coordination. Among these facilities, the designated medical institutions are responsible for the diagnosis, treatment, and registration of TB patients. Non-designated medical institutions are responsible for the initial screening, epidemic reporting, and referral of TB patients. Primary health care institutions are responsible for patient referrals and helping track and follow-up with patients. The CDC is responsible for planning, coordinating, monitoring, and controlling the response to the epidemic. In addition, the CDC is also responsible for prevention and technical guidance, publicity and education, performance evaluation, and other measures.

Study design

The data were obtained from the quarterly and annual reports of the Xinjiang Tuberculosis Management Information System. All diagnosed cases of active TB, new TB pleurisy, and extrapulmonary TB were registered by the designated medical institutions and county CDC, which recorded the basic information and treatment outcomes with regular follow-up and supervision. Simultaneously, the primary health care institutions monitored and reviewed the patients’ medications and other health measures.

After combining the patients’ case records with the treatment records in the report charts, we established statistical tables of treatment adherence for smear-positive TB patients in Xinjiang. We identified the population as smear-positive TB patients from July 2014 to June 2015 and collected basic information about the patients and their re-examinations at the end of second, fifth, and sixth (eighth) months and the treatment outcomes. To protect patient privacy, all information omitted the patient’s name and ID number. We defined good adherence as the completion of three sputum smear re-examinations and non-adherence as failure to complete three sputum smear re-examinations. The treatment outcomes included cure, treatment completion, tuberculosis death, failure, and drop-out. At the same time, we defined a clinical cure as disease-free status and treatment completion. We registered basic patient information including age, gender, ethnicity, occupation, household address, treatment classification, patient source, diagnosis patterns, actual management methods, etc.

By integrating the above data, we described the basic information for the smear-positive patients in Xinjiang from July 2014 to June 2015, explored the correlation between compliance
and the cure rate and survival rate of smear-positive TB patients and discussed the factors that influence treatment compliance.

Statistical analysis
The data were double-entered into Excel 2010 and analyzed using SPSS 18.0 for Windows by two procedures. Chi-squared tests were used to identify associations between patient adherence and the cure rate or death rate. Univariate logistic regression was used to analyze the relationship between each variable and adherence to assess independent risk factors for non-adherence. Variables with a P-value < 0.05 in the univariate analysis were included in the multivariable logistic regression models. The magnitude of association was measured by the odds ratio (OR) with a confidence interval (CI). The level of significance was set at P < 0.05.

Ethical considerations
All experiments were performed in compliance with medical ethics, and approved by the ethics committee at Xinjiang Medical University. Informed consents were obtained from human participants of this study.

Results
This study included 8289 patients with smear-positive cases of TB in Xinjiang from July 2014 to June 2015. The age of the study patients ranged from 5 to 102 years with an average age of 48.9 years. The study included 54.7% males and 45.3% females.

Regarding ethnicity, 14.4% of the patients were Han and 68.7% were Uighur. The local population accounted for 88.3%, and the floating population accounted for 11.7%. The study population was composed mainly of workers, farmers, and those involved in animal husbandry and fishery (78.5%). Newly treated patients represented 74.8% of the sample, and those undergoing retreatment accounted for 25.2%. Type III TB patients accounted for 99.1% of the study population; 1.4% of the patients were diagnosed by health examination, whereas 28.7% and 38.7% were diagnosed by illness or referral. The vast majority of patients (87.4%) were managed in full supervision mode (Table 1).

Treatment outcomes varied during the study. Cures were attained in 7039 (84.9%) patients. The treatment course was completed by 302 (3.6%) patients. Seven (0.0%) patients developed disease resistant to a single drug, whereas 23 (0.3%) patients were transferred to multi-drug resistant treatment. Ninety-eight (1.2%) patients experienced adverse effects, and 199 (2.4%) patients had treatment failure. Ninety-five (1.1%) patients died of TB, and 332 (4.0%) lost contact during follow-up. One (0.0%) patient was incorrectly diagnosed, and 193 (2.3%) died for other reasons not related to TB. We concluded that the number of clinically cured patients was 7341 (88.6%), excluding those who lost contact, wrongly diagnosed, or died of other diseases (including cardiovascular and cerebrovascular diseases, tumors, etc.). Patient compliance and attainment of a clinical cure were positively correlated (χ² = 0.536, P < 0.001). The difference was statistically significant. The association between the compliance of the population and the outcome of TB death was related (χ² = 0.326, P < 0.001). The difference was statistically significant (Tables 2 and 3).

We observed 1242 (15.0%) patients who had poor adherence to treatment and failed to complete three sputum smear visits. Treatment adherence was compared among different subgroups using a univariate logistic regression analysis. In this study, we found that those patients with poor adherence were elderly (P < 0.01), those from a floating population (P < 0.05), manual laborers (P < 0.01), those who were derived from referral and tracking (P < 0.01), or those who were self-medicated and

| Table 1 | Baseline characteristics of 8289 patients with smear-positive tuberculosis in Xinjiang |
|---------|-----------------------------------|
| **Basic information** | **N (%)** |
| **Gender** | |
| Male | 4532 (54.7) |
| Female | 3757 (45.3) |
| **Age** | |
| <15 | 92 (1.1) |
| 15-29 | 1924 (23.2) |
| 30-44 | 1607 (19.4) |
| 45-59 | 1740 (21.0) |
| >60 | 2926 (35.3) |
| **Ethnicity** | |
| Han | 1191 (14.4) |
| Hui | 302 (3.6) |
| Uyghur | 5693 (68.7) |
| Kazak | 862 (10.4) |
| Other | 241 (2.9) |
| **Permanent residence address** | |
| Non-mobile population | 7323 (88.3) |
| Floating population | 966 (11.7) |
| **Professional** | |
| Cadres | 147 (1.8) |
| Professional and technical personnel | 113 (1.4) |
| Food and beverage business | 50 (0.6) |
| Industry, agriculture, animal husbandry and fishery | 6510 (78.5) |
| Former employment or unemployment | 1062 (12.8) |
| Other | 407 (4.9) |
| **Treatment classification** | |
| Untreated | 6204 (74.8) |
| Retreated | 2085 (25.2) |
| **Diagnostic classification** | |
| Type I | 1 (0.0) |
| Type II + III | 64 (0.8) |
| Type III | 8216 (99.1) |
| Type IV + III | 7 (0.1) |
| Type V + III | 1 (0.0) |
| **Patient sources** | |
| Physical examination | 116 (1.4) |
| Visited doctor with symptoms | 2382 (28.7) |
| Because of the disease treatment is recommended | 1124 (13.6) |
| Referral | 3204 (38.7) |
| Tracking | 1402 (16.9) |
| Contacts to check | 20 (0.2) |
| Other | 41 (0.5) |
| **Actual management** | |
| Entire supervision | 7245 (87.4) |
| Entire management | 605 (7.3) |
| Phase strengthening supervision | 162 (2.0) |
| Self-administration | 3 (0.0) |
| Other | 274 (3.3) |
Table 2  Relationship between compliance and cure rate of smear-positive tuberculosis patients\textsuperscript{a}

| Compliance       | Cure (%) | Non-cure (%) | Total | $\chi^2$ | $P$  |
|------------------|----------|--------------|-------|----------|------|
| Compliance       | 6877 (98.7) | 93 (1.3)     | 6970  |          |      |
| Non-adherence    | 464 (58.5)  | 329 (41.5)   | 793   | 0.536    | $< 0.0001$ |
| Total            | 7341      | 422          | 7763  |          |      |

\textsuperscript{a} Note 1: from July 2014 to June 2015, there were 8289 patients in the Xinjiang cohort. Of these, 332 were unsuccessful due to loss, and 193 were died of other diseases. Note 2: clinical cure (cure, complete course of treatment), non-cure (single-drug resistant, multidrug-resistant treatment, adverse reaction, failure, tuberculosis death).

Table 3  Relationship between adherence and survival rate for smear-positive tuberculosis patients\textsuperscript{a}

| Compliance       | Death (%) | Non-death (%) | Total | $\chi^2$ | $P$  |
|------------------|-----------|---------------|-------|----------|------|
| Compliance       | 1 (0.0)   | 6969 (100.0)  | 6970  | 0.326    | $< 0.0001$ |
| Non-adherence    | 94 (11.9) | 699 (88.1)    | 793   |          |      |
| Total            | 95        | 7668          | 7763  |          |      |

\textsuperscript{a} Note 1: from July 2014 to June 2015, there were 8289 patients in the Xinjiang cohort. Of these, 332 were unsuccessful due to loss, 193 were died of other diseases, and 1 was incorrectly diagnosed. Note 2: death (tuberculosis death), non-death (cure, complete course of treatment, single-drug resistance, MDR-resistant, adverse reactions, failure).

supervised during the intensive phase. A multivariate logistic regression analysis controlled the effect of confounding factors and analyzed the associated risk factors for non-compliance. Univariate variables with $P$ values less than 0.05 were included in the multivariate logistic regression. The results showed that ethnicity, household address, treatment classification, patient source, and actual management were correlated with non-compliance (Table 4).

Discussion

TB threatens public health,\textsuperscript{18} and its prevalence hinders economic and social development. China is one of the 20 countries with highest proportion of TB cases worldwide as the “Stop TB Strategy” of the WHO,\textsuperscript{19} and Xinjiang has a serious TB epidemic situation. Effective treatment is essential to controlling the development and spread of TB; however, because anti-TB treatment requires long-term drug therapy, patients are prone to loss of compliance.\textsuperscript{20,21} Follow-up visits during treatment are important to monitor the response to the therapy and manage adverse events, which facilitates the supervision of patient treatment and prevention of lost cases.\textsuperscript{22}

In our study, approximately 15.0% of the patients were poorly adherent. This proportion was significantly higher than that of the Jiangsu (11.4%), Anhui (9.5%), and Ningxia (6.7%) patients.\textsuperscript{16} We also found that compliance was related to the level of TB cure rate and mortality. The cure rate of the compliance group (98.7%) was significantly higher than that of the non-compliance group (58.5%), and the mortality in the compliance group (0.0%) was significantly lower than in the non-compliance group (11.9%). Thus, it is necessary to improve the cure rate of the smear-positive population and reduce mortality by improving patient treatment compliance. However, recent Chinese studies have shown that most TB patients are unaware of the importance of return visits.\textsuperscript{23}

In the study, we found that gender and age were not associated with patient adherence to treatment, which was consistent with the results of previous studies.\textsuperscript{24} However, some studies have shown that male patients may be more likely to not comply with treatment because of their unhealthy lifestyles and physical over-confidence.\textsuperscript{25} The proportion of smear-positive TB patients in Xinjiang is high (85.6%), and the proportion of non-compliance among ethnic minorities is high. The Uighur patients accounted for 83.1% of the total number of non-compliant individuals. On the one hand, the high incidence of TB in Xinjiang ethnic minorities may be associated with the presence of TB susceptibility genes.\textsuperscript{26,27} On the other hand, most ethnic minorities lack TB-related knowledge and have not yet recognized the importance of long-term anti-TB treatment. Once the symptoms ease, these patients will be without medication. Some patients live in remote areas or in the country where treatment and inspection are not very convenient, resulting in many TB patients who cannot adhere to treatment and referral. We found that migrants were at risk for non-compliance, and 966 (11.7%) of the study population were migrants, with 17.6% being classified as non-adherent. Most of the floating population also lacks a fixed place, cannot adhere to timely referrals, are prone to treatment delays, and are not easy to manage and monitor. This study showed that adherence was significantly lower in newly treated patients than in retreated patients. The reason for this may be that re-treated patients can encounter drug resistance. During the retreatment process, these patients may lack confidence in treatment, causing the retreatment course to be longer. In this case, the symptoms may not improve, which can also lead to poor compliance. This study found that the patient source, along with patient referral and tracking, were significantly associated with compliance, possibly due to the fact that healthy examined people are more concerned about their own physical condition, which results in greater treatment compliance. The referral and tracking of
patients as recommended by the CDC intervention may result in lower patient initiative for treatment. This study also found that intensive phase supervision is a risk factor for patient compliance. Although some patients in the intensive phase have very good compliance under supervision, if the publicity and supervision are insufficient during the continuing period, intermittent treatment and irregular follow-up may result, which will affect the treatment. Research has also shown that during the entire process of supervision and management, patients have good treatment compliance.

In recent years, there has been a high incidence of new cases of TB worldwide because of the increased population, the floating population, the increased incidence of drug-resistant TB, latent infection, and the AIDS epidemic.\textsuperscript{28,29} In 2015, the WHO proposed a moratorium on TB that aimed to reduce the incidence of TB by 90% by 2035.\textsuperscript{30} At present, there is no early diagnostic procedure for TB, leading to delayed treatment in most TB patients.\textsuperscript{31} The number of physical workers in the study accounted for 78.5% of the total number of smear-positive patients, and most of these individuals lacked basic knowledge of TB. It is easy to delay healthcare until symptoms appear, which results in delayed treatment.

Some studies have shown that family care and support played an important role during TB treatment.\textsuperscript{32} However, the remaining

### Table 4  Analysis of influential factors of the treatment compliance of 8289 smear-positive tuberculosis patients in Xinjiang

| Basic information                  | N          | Non-adherence n (%) | OR (95% CI) | P       | OR (95% CI) | P       |
|------------------------------------|------------|---------------------|-------------|---------|-------------|---------|
| **Gender**                         |            |                     |             |         |             |         |
| Male                               | 4532       | 705 (15.6)          | 1           | 0.109   | 1           | 0.080   |
| Female                             | 3757       | 537 (15.0)          | 0.905       | 0.888   | 0.777–1.014 | 0.080   |
| **Age**                            |            |                     |             |         |             |         |
| ~15                                | 92         | 7 (7.6)             | 1           |         |             |         |
| ~30                                | 1924       | 200 (10.4)          | 1.409       | 0.890   | 0.383–2.071 | 0.787   |
| ~45                                | 1607       | 177 (11.0)          | 1.503       | 0.848   | 0.360–1.998 | 0.705   |
| ~60                                | 1740       | 254 (14.6)          | 2.076       | 1.083   | 0.461–2.543 | 0.854   |
| >60                                | 2926       | 604 (20.6)          | 3.159       | 1.628   | 0.697–3.797 | 0.261   |
| **Ethnics**                        |            |                     |             |         |             |         |
| Han                                | 1191       | 88 (7.4)            | 1           |         |             |         |
| Uyghur                             | 5693       | 1032 (12.5)         | 2.775       | 3.010   | 2.330–3.890 | 0.000   |
| Kazak                              | 862        | 76 (8.9)            | 1.212       | 1.677   | 1.180–2.384 | 0.004   |
| Other                              | 241        | 30 (0.4)            | 1.782       | 1.926   | 1.188–3.122 | 0.008   |
| **Household address**              |            |                     |             |         |             |         |
| Non-mobile population              | 7323       | 1072 (14.6)         | 1           |         |             |         |
| Floating population                | 966        | 170 (17.6)          | 1.245       | 1.329   | 1.071–1.649 | 0.010   |
| **Professional**                   |            |                     |             |         |             |         |
| Cadres                            | 147        | 15 (10.2)           | 1           |         |             |         |
| Professional and technical personnel | 113    | 11 (9.7)           | 0.949       | 0.835   | 0.346–2.014 | 0.689   |
| Food and beverage business        | 50         | 6 (12.0)           | 1.200       | 1.290   | 0.439–3.283 | 0.657   |
| Industry, agriculture, animal husbandry and fisheries | 6510 | 1033 (15.9) | 1.660       | 1.004   | 0.564–1.787 | 0.990   |
| Former and unemployment           | 1062       | 148 (13.9)          | 1.425       | 1.195   | 0.656–2.176 | 0.561   |
| Other                             | 407        | 29 (7.1)            | 0.675       | 0.722   | 0.353–1.475 | 0.371   |
| **Treatment classification**       |            |                     |             |         |             |         |
| Untreated                          | 6204       | 756 (12.2)          | 1           |         |             |         |
| Retreated                          | 2085       | 486 (23.3)          | 2.190       | 1.653   | 1.433–1.907 | 0.000   |
| **Diagnostic classification**      |            |                     |             |         |             |         |
| Type III                           | 8216       | 1233 (15.0)         | 1           |         |             |         |
| Other                              | 73         | 9 (0.1)             | 0.796       |         | 0.395–1.604 |         |
| **Patients sources**               |            |                     |             |         |             |         |
| Physical examination               | 116        | 18 (15.5)           | 1           |         |             |         |
| Visited doctor with symptoms       | 2382       | 285 (12.0)          | 0.740       | 4.117   | 2.106–8.047 | 0.000   |
| Because of the disease treatment is recommended | 1124 | 139 (12.4) | 0.768       | 3.013   | 1.526–5.949 | 0.001   |
| Referral                           | 3204       | 528 (16.5)          | 1.074       | 6.326   | 3.247–12.325 | 0.000   |
| Tracking                           | 1402       | 260 (18.5)          | 1.240       | 6.513   | 3.307–12.830 | 0.000   |
| Contacts to check                  | 20         | 2 (10.0)            | 0.605       | 3.416   | 0.552–21.133 | 0.186   |
| Other                              | 41         | 10 (24.4)           | 1.756       | 7.257   | 2.587–20.354 | 0.000   |
| **Actual management**              |            |                     |             |         |             |         |
| Entire supervision                 | 7245       | 929 (12.8)          | 1           |         |             |         |
| Entire management                  | 605        | 40 (6.6)            | 0.481       | 0.409   | 0.293–0.572 | 0.000   |
| Phase strengthening supervision    | 162        | 75 (46.3)           | 5.861       | 6.214   | 4.453–8.673 | 0.000   |
| Self-administration                | 3          | 1 (33.3)            | 3.399       | 3.696   | 0.308–41.377 | 0.289   |
| Other                              | 274        | 197 (71.9)          | 17.394      | 19.967  | 14.551–27.397 | 0.000   |
TB patients represent a serious psychological burden and stress. We believe that grass-roots medical institutions should strengthen the basic knowledge of TB-related advocacy, improve patient awareness of TB, and provide some psychological support for those patients undergoing repeat treatment. Family members should be encouraged to care for one another and supervise patient medication and regular referral. To reduce the financial burden of TB patients, the state provides TB patients with free anti-TB drugs and necessary inspection items, and although this free policy covers all of the typical TB patients, it does not include patients with adverse reactions to treatment or drug-resistant patients who require second-line anti-TB drugs. However, the treatment enthusiasm is not high for some farmers and herdsmen in remote areas because of the distance and the extra cost. In this regard, the relevant government departments should expand their focus on supporting this part of the population.

Limitations

There are still some limitations of this study. Compliance for TB treatment includes medication adherence and compliance, and this study discussed only the factors that influence compliance. The basic patient information did not cover economic and cultural factors.

Conclusion

The Xinjiang TB epidemic situation remains grim. Smear-positive patients had a higher proportion of non-adherence. Ethnicity, residence address, classification, treatment regimen, and the actual source of management were associated with non-compliance. Non-compliance increased the difficulty of treatment and risk of death. The relevant medical departments should strengthen the supervision and intervention of the TB treatment process, strengthen TB-related basic knowledge propaganda, raise awareness of TB patients, and give financial and policy support to farmers and herdsmen in remote areas to improve anti-TB treatment adherence.

Conflicts of interest

All authors do not have a conflict of interest.

Acknowledgements

The authors thank all the participants in the study for the successful completion of the research efforts, Wang Jing and Li Yuehua for assistance with the design of the study and guidance in writing the article, Li Rongrong for assistance with the statistics and analysis as well as general guidance, and the authors’ remaining colleagues for the data collection and helping to complete the article. Study supported by grants from the State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases (SKLIB-XJMDR-2012-2, SKLIB-XJMDR-2014-14, SKLIB-XJMDR-2016-4) and Major science and technology project in Xinjiang Uygur autonomous region (2017A03006-2).

References

1 W. Wang, B. Mathema, Y. Hu, Q. Zhao, W. Jiang and B. Xu, Role of casual contacts in the recent transmission of tuberculosis in settings with high disease burden, Clin. Microbiol. Infect., 2014, 20, 1140–1145.
2 World Health Organization, Global Tuberculosis Report, World Health Organization, Geneva, 2015.
3 A. Hassan, M. Fattouh, I. Atteya, H. Mohammadene and H. Ahmed, Validation of a rapid tuberculosis PCR assay for detection of MDR-TB patients in Sohag University Hospital, Stud. Conserv., 2014, 56(4), 281–297.
4 G. N. Gurung, P. S. Chhetri and N. Jha, Economic impact of pulmonary tuberculosis on patients and their families of Dharan municipality, Nepal Med. Coll. J., 2012, 14, 196–198.
5 H. Duanmu, The prevalence of pulmonary tuberculosis in a national survey across China in 2010, Zhonghua Jie He He Xi Za Zhi, 2012, 35, 665–668.
6 P. Mijiti, Y. Li, X. Feng, et al., Prevalence of pulmonary tuberculosis in western China in 2010–11: a population-based, cross-sectional survey, Lancet Glob. Health., 2016, 4(7), e485.
7 A. Wubuli, F. Xue, D. Jiang, X. Yao, H. Upur and Q. Wushouer, Socio-demographic predictors and distribution of pulmonary tuberculosis (TB) in Xinjiang, China: a spatial analysis, PLoS One, 2015, 10, e0144010.
8 G. Maartens and R. J. Wilkinson, Tuberculosis. Lancet., 2007, 370, 2030–2043.
9 P. Nahid, L. G. Jarlsberg, I. Rudoy, B. C. de Jong, A. Unger, L. M. Kawamura, et al. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis, BMC Infect. Dis., 2011, 11, 1.
10 H. Shen, L. Zhu, Y. Zhou, W. Xu, W. Lu and J. Wang, Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study, BMC Health Serv. Res., 2009, 9, 169.
11 M. Rocha, S. Pereira, L. Ferreira and H. Barros, The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen, Eur. Respir. J., 2003, 21, 785–788.
12 A. J. Manders, A. Banerjee, H. W. van den Borne, A. D. Harries, G. J. Kok and F. M. Salaniponi, Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase, International Journal of Tuberculosis and Lung Disease, 2001, 5, 838–842.
13 C. T. Kangombe, A. D. Harries, K. Ito, T. Clark, T. E. Nyirenda, W. Aldis, et al., Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB., International Journal of Tuberculosis and Lung Disease, 2004, 8, 829–836.
14 Y. Tang, M. Zhao, Y. Wang, Y. Gong, X. Yin, A. Zhao, et al., Non-adherence to anti-tuberculosis treatment among internal migrants with pulmonary tuberculosis in Shenzhen, China: a cross-sectional study, BMC Public Health, 2015, 15, 474.
15 W. Xu, W. Lu, Y. Zhou, L. Zhu, H. Shen and J. Wang, Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study, *BMC Health Serv. Res.*, 2009, 9, 1–8.
16 S. Yao, W. H. Huang, S. van den Hof, S. M. Yang, X. L. Wang, W. Chen, et al. Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China, *BMC Health Serv. Res.*, 2011, 11, 1–8.
17 L. Adams, K. Bergstrom, D. Bleed, C. Colvin and E. Eckert, *Compendium of indicators for monitoring and evaluating national tuberculosis programs*, World Health Organization, Geneva, 2004.
18 L. F. Assebe, H. L. Reda, A. D. Wubeneh, W. T. Lerebo and S. M. Lambert, The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study, *BMC Public Health*, 2015, 15, 1–9.
19 M. Uplekar, D. Weil, K. Lonnroth, et al., WHO’s new end TB strategy, *Lancet*, 2015, 385(9979), 1799–1801.
20 D. S. Pope and R. E. Chaisson, TB treatment: as simple as DOT?, *International Journal of Tuberculosis and Lung Disease*, 2003, 7, 611–615.
21 OMS, Global tuberculosis control: surveillance, planning, financing – WHO report 2005, *Indian J. Med. Res.*, 2008, 58, 89–90.
22 World Health Organization, *Status of tuberculosis in the 22 high-burden countries, country profiles*, World Health Organization, Geneva, 1999.
23 X. Ai, K. Men, L. Guo, T. Zhang, Y. Zhao, X. Sun, et al., Factors associated with low cure rate of tuberculosis in remote poor areas of Shaanxi Province, China: a case control study, *BMC Public Health*, 2010, 10, 112.
24 F. R. Kayigamba, M. I. Bakker, V. Mugisha, L. De Naeyer, M. Gasana, F. Cobelens, et al., Adherence to tuberculosis treatment, sputum smear conversion and mortality: a retrospective cohort study in 48 Rwandan clinics, *PLoS One*, 2013, 8, e73501.
25 X. Lei, K. Huang, Q. Liu, Y. F. Jie and S. L. Tang, Are tuberculosis patients adherent to prescribed treatments in China? Results of a prospective cohort study, *Infect Dis. Poverty*, 2016, 5, 1–9.
26 X. Wang, L. J. Ren, X. L. Li, F. Wu, L. Zhang and W. J. Zhang, A study on the correlation between the polymorphism of HLA-DR, DQ genes and the susceptibility to pulmonary tuberculosis in a Uyghur population from Xinjiang, *Chin. J. Antituberc.*, 2011, 33, 197–203.
27 P. He, X. Wang, Y. Liu, F. Wu, P. Wang, L. Zhang, et al., Association of the polymorphism for the HLA-DRB 1 gene and the susceptibility to tuberculosis in population of Xinjiang Kazaks, *Xiandai Shengwuyixue Jinzhan*, 2010, 10, 90–92.
28 R. Ragonnet, J. M. Trauer, J. T. Denholm, B. J. Marais and E. S. McBryde, High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?, *BMC Infect. Dis.*, 2017, 17, 36.
29 R. Maimaiti, Y. Zhang, K. Pan, P. Mijiti, M. Wubili, M. Musa, et al., High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China, *BMC Infect. Dis.*, 2017, 17, 15.
30 World Health Organization, Draft report of the sixty-seventh world health assembly on global strategy and targets for tuberculosis prevention, *Care and Control after 2015*, World Health Organization, Geneva, 2015.
31 H. E. Leylabadlo, H. S. Kafil, M. Yousefi, M. Aghazadeh and M. Asgharzadeh, Pulmonary tuberculosis diagnosis: where we are?, *Tuberc. Respir. Dis.*, 2016, 79, 134–142.
32 B. Chen, Y. Peng, L. Zhou, C. Chai, H. C. Yeh, S. Chen, et al., Social support received by multidrug-resistant tuberculosis patients and related factors: a cross-sectional study in Zhejiang Province, People’s Republic of China, *Patient Prefer. Adher.*, 2016, 10, 1063.